X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ELDER PHARMA ALEMBIC PHARMA/
ELDER PHARMA
 
P/E (TTM) x 26.9 -0.2 - View Chart
P/BV x 5.4 0.1 5,373.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALEMBIC PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
ELDER PHARMA
Jun-14
ALEMBIC PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs645380 169.8%   
Low Rs470188 249.9%   
Sales per share (Unadj.) Rs166.1491.2 33.8%  
Earnings per share (Unadj.) Rs21.9-3.2 -688.3%  
Cash flow per share (Unadj.) Rs27.514.4 190.8%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs117.8376.5 31.3%  
Shares outstanding (eoy) m188.5220.54 917.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.6 580.5%   
Avg P/E ratio x25.5-89.3 -28.5%  
P/CF ratio (eoy) x20.319.7 102.9%  
Price / Book Value ratio x4.70.8 627.5%  
Dividend payout %18.30-   
Avg Mkt Cap Rs m105,0905,833 1,801.5%   
No. of employees `000NANA-   
Total wages/salary Rs m6,2282,179 285.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,30810,089 310.3%  
Other income Rs m70257 27.4%   
Total revenues Rs m31,37810,346 303.3%   
Gross profit Rs m6,431-792 -812.1%  
Depreciation Rs m1,055361 291.9%   
Interest Rs m342,756 1.2%   
Profit before tax Rs m5,413-3,653 -148.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m1,204125 961.6%   
Profit after tax Rs m4,128-65 -6,317.1%  
Gross profit margin %20.5-7.8 -261.7%  
Effective tax rate %22.2-3.4 -649.0%   
Net profit margin %13.2-0.6 -2,035.7%  
BALANCE SHEET DATA
Current assets Rs m18,2479,240 197.5%   
Current liabilities Rs m11,2359,998 112.4%   
Net working cap to sales %22.4-7.5 -298.2%  
Current ratio x1.60.9 175.7%  
Inventory Days Days8646 184.8%  
Debtors Days Days6160 102.4%  
Net fixed assets Rs m20,03510,124 197.9%   
Share capital Rs m377206 183.3%   
"Free" reserves Rs m21,8245,582 391.0%   
Net worth Rs m22,2017,734 287.1%   
Long term debt Rs m5,0004,889 102.3%   
Total assets Rs m39,41122,882 172.2%  
Interest coverage x160.2-0.3 -49,246.4%   
Debt to equity ratio x0.20.6 35.6%  
Sales to assets ratio x0.80.4 180.2%   
Return on assets %10.611.8 89.8%  
Return on equity %18.6-0.8 -2,200.4%  
Return on capital %19.722.3 88.4%  
Exports to sales %46.43.0 1,527.7%   
Imports to sales %10.50.4 2,458.6%   
Exports (fob) Rs m14,535307 4,740.6%   
Imports (cif) Rs m3,28843 7,629.5%   
Fx inflow Rs m14,722307 4,801.6%   
Fx outflow Rs m7,026125 5,607.2%   
Net fx Rs m7,696181 4,244.8%   
CASH FLOW
From Operations Rs m3,12411,754 26.6%  
From Investments Rs m-8,844-561 1,577.8%  
From Financial Activity Rs m5,026-6,762 -74.3%  
Net Cashflow Rs m-6934,432 -15.6%  

Share Holding

Indian Promoters % 74.1 39.6 187.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 7.5 38.7%  
FIIs % 9.1 16.8 54.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.1 38.5%  
Shareholders   49,328 16,479 299.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS